title: Glycans are involved in RANTES binding to CCR5 positive as well as to CCR5 negative cells.
abstract: We show that cell surface glycans, sialic acid and mannose-containing species, are involved beside glycosaminoglycans (GAGs), heparan sulfate and chondroitin sulfate in the binding of full length (1--68) RANTES not only to CCR5 positive human primary lymphocytes or macrophages but also to CCR5 negative monocytic U937 cells. Pretreating the cells with neuraminidase, heparitinase, chondroitinase or adding soluble glycans such as mannan or GAGs (heparin or chondroitin sulfate), significantly inhibited RANTES binding. Such effects were not observed with truncated (10--68) RANTES. Heat-denaturation of (1--68) RANTES strongly decreased its binding to the cells, demonstrating involvement of the three-dimensional structure. Accordingly, full length, but not truncated (10--68) RANTES, specifically bound to soluble mannan as well as to mannose-divinylsulfone-agarose affinity matrix and to soluble heparin or chondroitin sulfate as well as to heparin-agarose. Soluble heparin exerts, depending on its concentration, inhibitory or enhancing effects on RANTES binding to mannose-divinylsulfone-agarose, which indicates that RANTES interaction with glycans is modulated by GAGs. These data demonstrate that full length RANTES, but not its (10--68) truncated counterpart, interacts with glycans and GAGs, in soluble forms or presented either by affinity matrices or CCR5 positive as well as CCR5 negative cells.
authors.affiliation: Laboratoire de Biologie Cellulaire JE 2138, Faculté de Médecine, Université Paris XIII, 74 rue Marcel Cachin, 93017 Bobigny, France.
authors.forename: E
authors.initials: E
authors.lastname: Mbemba
authors.forename: H
authors.initials: H
authors.lastname: Slimani
authors.forename: A
authors.initials: A
authors.lastname: Atemezem
authors.forename: L
authors.initials: L
authors.lastname: Saffar
authors.forename: L
authors.initials: L
authors.lastname: Gattegno
mesh_terms: D002460:Cell Line; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002809:Chondroitin Sulfates / Q000494:pharmacology; D002810:Chondroitinases and Chondroitin Lyases; D006025:Glycosaminoglycans / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008264:Macrophages; D008351:Mannans / Q000494:pharmacology; D009439:Neuraminidase; D011133:Polysaccharide-Lyases; D011134:Polysaccharides / Q000378:metabolism*; D019713:Receptors, CCR5 / Q000378:metabolism*; D012685:Sepharose / Q000031:analogs & derivatives
chemical_list: D018946:Chemokine CCL5; D006025:Glycosaminoglycans; D008351:Mannans; D011134:Polysaccharides; D019713:Receptors, CCR5; C037405:heparin-sepharose; D006493:Heparin; D002809:Chondroitin Sulfates; D012685:Sepharose; D009439:Neuraminidase; D002810:Chondroitinases and Chondroitin Lyases; D011133:Polysaccharide-Lyases; C021349:heparitinsulfate lyase